Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

(2010) SHARP Collaborative Group   AMERICAN HEART JOURNAL

An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

(2010) Robert M. Califf et al.   AMERICAN HEART JOURNAL

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)

(2009) Jennifer G. Robinson et al.   AMERICAN JOURNAL OF CARDIOLOGY

Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)

(2009) Franklin Zieve et al.   AMERICAN JOURNAL OF CARDIOLOGY

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

(2009) Kornelia Kotseva et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study

(2009) M. Farnier et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Dyslipidemia in type 2 diabetes mellitus

(2009) Arshag D Mooradian   Nature Reviews Endocrinology

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

(2008) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.

(2008) Scott E. Conard et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease

(2008) Lawrence A. Leiter et al.   AMERICAN JOURNAL OF CARDIOLOGY

Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors

(2008) Z. Ravid et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

The intestine as a regulator of cholesterol homeostasis in diabetes

(2008) Gerald H. Tomkin   ATHEROSCLEROSIS SUPPLEMENTS

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

(2008) J. D. Brunzell et al.   DIABETES CARE

Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

(2008)   LANCET